Improved systemic metabolism and adipocyte biology in miR-150 knockout mice

Minsung Kang1, Xiaobing Liu1, Yuchang Fu1

  • 1Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.

Abstract

Insights

MicroRNA-150 (miR-150) knockout mice exhibit reduced body weight, fat mass, and food intake, alongside improved insulin sensitivity and glucose tolerance. These findings suggest miR-150 is a potential therapeutic target for obesity and metabolic disorders.

Area of Science:

  • Molecular Biology
  • Metabolic Research
  • Genetics

Background:

  • MicroRNAs (miRNAs) are short non-coding RNAs regulating protein expression.
  • The specific role of miRNAs in obesity and cardiometabolic diseases is not fully understood.
  • Previous research indicated miR-150 influences lipid metabolism.

Purpose of the Study:

  • To investigate the systemic metabolic effects of miR-150.
  • To examine the impact of miR-150 on adipocyte biology.
  • To determine if miR-150 plays a role in obesity and insulin resistance.

Main Methods:

  • Assessed metabolic phenotypes (body weight, food intake, body composition, glucose tolerance, insulin sensitivity) in wild-type (WT) and miR-150 knockout (KO) male mice fed a high-fat diet.
  • Analyzed molecular changes in epididymal adipose tissue using quantitative reverse transcription PCR (qRT-PCR) and Western blotting.

Main Results:

  • miR-150 KO mice showed significantly lower body weight, reduced fat mass, and increased lean mass compared to WT mice.
  • KO mice exhibited decreased food consumption, increased circulating leptin, and enhanced insulin sensitivity and glucose tolerance.
  • Absence of miR-150 led to increased mTOR expression, PGC-1α, PPARα, and glycerol kinase, promoting triglyceride degradation and lipid oxidation.

Conclusions:

  • miR-150 knockout mice demonstrated significant metabolic benefits, including reduced body weight, energy intake, and improved lipid metabolism.
  • miR-150 emerges as a potential biomarker and a novel therapeutic target for managing obesity and insulin resistance.